Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 5
Submit an article Journal homepage
1,500
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

Modulation of bone marrow microenvironment following ruxolitinib therapy in myelofibrosis

Giovanni CaocciHematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy and Correspondence[email protected]
,
Antonio MaccioniPathology Unit, SS. Trinità Hospital, ASL 8, Cagliari, Italy
,
Francesca MurgiaHematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy and
,
Alessandra PerraHematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy and
,
Monica UsaiHematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy and
,
Michela PigaPathology Unit, SS. Trinità Hospital, ASL 8, Cagliari, Italy
,
Roberto MasciaPathology Unit, SS. Trinità Hospital, ASL 8, Cagliari, Italy
&
Giorgio La NasaHematology Unit, Department of Medical Sciences, Bone Marrow Transplant Center, R. Binaghi Hospital, University of Cagliari, Cagliari, Italy and
show all
Pages 1215-1218 | Received 14 Jun 2015, Accepted 25 Jul 2015, Published online: 05 Oct 2015

References

  • Tefferi A. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2011; 86: 1017–1026.
  • Tefferi A, Thiele J, Vannucchi AM, et al. An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia 2014; 28: 1407–1413.
  • Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787–798.
  • Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013; 98: 1865–1871.
  • Kantarjian HM, Silver RT, Komrokji RS, et al. Ruxolitinib for myelofibrosis–an update of its clinical effects. Clin Lymphoma Myeloma Leuk 2013; 13: 638–645.
  • Breccia M, Molica M, Colafigli G, et al. Improvement of bone marrow fibrosis with ruxolitinib: Will this finding change our perception of the drug? Expert Rev Hematol 2015; 4: 387–389.
  • Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Long-term intervention effects on bone marrow morphology in myelofibrosis: Patients treated with ruxolitinib and best available therapy. Haematologica 2013; 98: abstract 591.
  • Wilkins BS, Radia D, Woodley C, et al. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 2013;98: 1872–1876.
  • Molica M, Serrao A, Saracino R, et al. Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: New endpoint to achieve? Ann Hematol 2014; 93: 1951–1952.
  • Al-Ali HK, Hubert K, Lange T, et al. Complete clinical, histopathologic and molecular remission of primary myelofibrosis with long-term treatment with the JAK1/2 inhibitor ruxolitinib. Blood 2014; 124: abstract 1836.
  • Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Changes in activated bone marrow macrophages and mast cells in patients with myelofibrosis following ruxolitinib therapy. Blood 2014; 124: abstract 3184.
  • Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Ruxolitinib-induced modulation of bone marrow microenvironment in patients with myelofibrosis is associated with inflammatory cytokine levels. Blood 2014; 124:abstract 3182.
  • Kvasnicka HM, Thiele J, Bueso-Ramos CE, et al. Ruxolitinib therapy effectively modulates CD34+ hematopoietic progenitors and bone marrow angiogenesis in patients with myelofibrosis. Blood 2014; 124: abstract 4578.
  • Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009; 115: 3842–3847.
  • Travlos GS. Normal structure, function, and histology of the bone marrow. Toxicol Pathol 2006; 34: 548–565.
  • Thiele JL, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128–1132.
  • Pozdnyakova O, Wu K, Patki A, et al. High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. Mod Pathol 2014; 27: 1447–1454.
  • Caocci G, Murgia F, Podda L, et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 2014; 28: 225–227.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.